| Name | Title | Contact Details |
|---|
The RAMPF Group stands for engineering and chemical solutions and caters to the economic and ecological needs of industry. Our range of competences includes: 🧪 Production and recycling of materials for modeling, lightweight construction, bonding, and protection ⚙️ Technical production systems for precise, dynamic positioning and automation, as well as technologies for complex composite parts production 💡 Comprehensive range of solutions and services, particularly for innovative customer-specific requirements Please find our imprint here: https://www.rampf-group.com/de/impressum/ https://www.rampf-group.com/en/imprint/
The Legal Marketing Association (LMA) is a not-for-profit organization established in 1985, dedicated to supporting professionals in legal marketing, business development, client service, and communications. With over 4,200 members from 49 U.S. states and 28 countries, LMA serves a diverse community that includes in-house marketers, consultants, lawyers, and marketing students. The organization emphasizes ethical standards, thought leadership, and professional advocacy. LMA provides a range of professional development resources, including educational programs, networking opportunities, and publications. Its Body of Knowledge (BoK) framework defines essential skills for legal marketers, while various events and webinars promote knowledge sharing and innovation. LMA fosters a collaborative environment where members can connect, share best practices, and advance their careers in the evolving landscape of legal marketing.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
Kersia Group is a global leader in biosecurity and food safety, focused on ensuring the safety of food production, processing, distribution, and consumption. The company aims to create a food-safe world by providing innovative and sustainable solutions that prevent diseases and contamination throughout the food supply chain. Kersia offers a variety of services to enhance food safety and operational performance. These include plant sanitation assessments, inventory usage management, annual cleaning validation, routine plant visits, and sanitation audits. The company collaborates with clients to optimize sanitation programs, ensuring high hygiene standards and compliance with regulatory requirements. With a significant presence in the United States and headquartered in France, Kersia USA specifically addresses food safety challenges in the meat and poultry processing sectors. The company is dedicated to supporting various industries, including dairy and healthcare, by delivering tailored solutions that enhance operational efficiency.